Compare Hershey Co (HSY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs TG Therapeutics Inc — how do they compare? Hershey Co trades at $170.02 (market cap $34.83B), while TG Therapeutics Inc trades at $54.27 (market cap $8.26B). The key difference: Hershey Co is far larger — about 4.2× TG Therapeutics Inc's market cap, and Hershey Co pays a 3.38% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HSY | TGTX | |
|---|---|---|
Market Cap | $34.83B | $8.26B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $59.06 |
52-Week Low | $162.31 | $26.39 |
Enterprise Value | $39.63B | $8.50B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $171.72, showing modest daily gains of 0.18%. The stock faces bearish technical signals with recent price action near support at $170, while fundamentals reveal mixed performance with strong earnings beats but compressed margins. Recent Q1 2026 EPS of $2.35 exceeded expectations by 15%, though net income margin declined to 7.55% in 2025 from 19.82% in 2024 due to cocoa cost pressures. The company maintains solid cash flow generation with $2.28B operating cash flow in 2025.
Hershey presents a cautious opportunity as margin recovery begins in Q2 2026, with analyst consensus target of $208.42 offering 21% upside. However, volume concerns and competitive pressures pose near-term risks. The 3.3% dividend yield provides income support while investors await evidence of sustained sales volume recovery and margin expansion in upcoming earnings.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
